Drug Profile
Research programme: monoclonal antibody therapeutics - Achaogen/Ligand Pharmaceuticals
Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Crystal Bioscience
- Developer Achaogen; Ligand Pharmaceuticals
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acinetobacter infections; Gram-negative infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Acinetobacter-infections in USA (Parenteral)
- 28 May 2023 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (Parenteral)
- 30 Apr 2019 Preclinical trials in Acinetobacter infections in USA (Parenteral) (Achaogen pipeline, April 2019)